Zevra Therapeutics reports Q3 EPS (1c), consensus (2c)

Reports Q3 revenue $26.06M, consensus $26.64M. “Zevra is well-positioned for continued growth, driven by the strong performance of MIPLYFFA and the meaningful impact we are delivering to patients with Niemann-Pick disease type C,” said Neil F. McFarlane, Zevra’s President and Chief Executive Officer. “We have generated strong revenue and a solid operating runway that enables us to execute on our strategic priorities and invest in building Zevra into a leading rare disease company.”